News

Exciting Q1-2025 Financial Overview for Stack Capital Group

Exciting Q1-2025 Financial Overview for Stack Capital Group

Overview of Financial Performance

Stack Capital Group Inc. has recently shared noteworthy financial results for the quarter ending March 31, 2025. The company, which is actively involved in investment opportunities across various sectors, reports all figures in Canadian Dollars unless stated otherwise. As of March 31, 2025, the Book Value per Share (BVpS) was recorded at $12.06, a slight decline from $12.29 noted at the end of the previous year.

Significant Portfolio Developments

One of the standout achievements for Stack Capital this quarter was the public debut of its initial portfolio investment, CoreWeave, an emerging player in AI infrastructure. The company invested an additional US$2.2 million in CoreWeave just before its IPO on March 28, 2025. This investment underscored Stack Capital's belief in CoreWeave's potential within a rapidly evolving market. Following this IPO, the investment was notably adjusted by a US$2.4 million write-down due to CoreWeave's closing price of US$37.08 as of March 31, 2025. Fortunately, there has been a recovery in CoreWeave’s share price to US$53.60 by May 7, 2025, indicating a potential benefit to Stack Capital's BVpS by an estimated $0.45 since quarter-end. The company is optimistic about CoreWeave's upcoming quarterly results, which might trigger further price growth, especially as global economic conditions stabilize.

Investment Impact from Shield AI

During the first quarter, another significant investment was made by Shield AI, which raised US$240 million, boosting its valuation to US$5.3 billion. This investment bolstered its value in Stack Capital's portfolio. Shield AI is pioneering advancements in AI pilot technology and has established partnerships with major aerospace leaders, Boeing and Airbus U.S. Space & Defense. These collaborations aim to enhance unmanned capabilities, reinforcing Shield AI's strong market position.

Exciting Advancements in Space Technology

In another significant event, SpaceX received FAA approval to ramp up its Starship launch frequency from five to 25 launches annually. This increased capacity is expected to accelerate the deployment of next-generation satellites, enhancing services like its Starlink satellite communications. As Stack Capital has strategic interests in SpaceX, this approval represents a promising opportunity for further portfolio growth.

Innovations in Robotics

March also witnessed Locus Robotics unveil its cutting-edge ‘Array’ autonomous mobile robot at major international trade shows. This innovative AI-powered fulfillment system is engineered to reduce manual labor significantly within warehouses by streamlining processes like order picking and returns. Such technological advances hint at the future direction of e-commerce operations, showcasing the potential for increased efficiency and cost savings.

Omio's International Expansion

After the quarter ended, Omio, a multi-modal travel platform, announced its expansion into Southeast Asia, adding over 14,000 bus routes. This strategic move not only enhances its current offerings but positions Omio to become a comprehensive travel provider by Q4-2025. With plans to include ferry and rail services, the Omio app is set to transform travel across three continents and 45 countries.

Financial Position Summary

As of the end of Q1 2025, Stack Capital's overall Book Value stood at $129.7 million. Here's a closer look at the components that make up the Book Value per Share:

Breakdown of Investments

Stack Capital's diversified portfolio showcases a strong variety of investments in high-growth industries:

  • SpaceX (Space Exploration & Satellite Communications): $2.18
  • Locus Robotics (Autonomous Robots): $1.32
  • Canva (Graphic Design): $1.29
  • Omio (Travel & Leisure): $1.11
  • Hopper (Travel & Leisure): $1.07
  • Newfront Insurance (Insurance & Benefits): $1.07
  • Prove Identity (Cyber-Security): $1.02
  • CoreWeave (AI Hyper-Scaler): $1.01
  • Bolt Financial (E-Commerce): $0.50
  • Shield AI (Military Defence): $0.39
  • Varo Money (Neo-Banking): $0.13
  • Cash: $1.00
  • Net Other Assets: $(0.03)

The calculated BVpS is represented as follows: $12.06, emphasizing Stack Capital's ongoing commitment to enhancing shareholder value through strategic investments.

About Stack Capital

Stack Capital operates as an investment holding company, aiming to engage in equity, debt, and other securities of private growth businesses. Through this structure, shareholders gain access to a diverse investment portfolio in the private market while benefiting from enhanced liquidity thanks to the Company’s listings on the TSX. This unique approach allows Stack Capital to concentrate on maximizing long-term performance across its selective investments, which are not typically accessible to the average Canadian investor.

For inquiries, please contact:
Brian Viveiros
VP, Corporate Development, and Investor Relations
647.280.3307
brian@stackcapitalgroup.com

Frequently Asked Questions

What is Stack Capital Group's primary business focus?

Stack Capital focuses on investing in equity, debt, and other securities of growth-to-late-stage private businesses.

What major investment milestone did Stack Capital achieve in Q1-2025?

The prominent milestone was the public IPO of its first portfolio investment, CoreWeave.

What strategic partnerships did Shield AI establish recently?

Shield AI formed strategic partnerships with Boeing and Airbus U.S. Space & Defense to advance unmanned aerial capabilities.

How is Stack Capital addressing market volatility?

Stack Capital is optimistic about its investments' potential growth amid expected improvements in global economic conditions.

How can investors learn more about Stack Capital's performance and plans?

Investors can visit Stack Capital's official website for detailed information and updates.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

BioVid Debuts AI to Mimic Physician Decision-Making

Updated Category News Views 47

Revolutionizing Understanding: BioVid Mimetics™ Now here's something that's shaking the research tree: BioVid's launching Mimetics™, and it's a big deal. They've come up with AI that can mirror how physicians think and decide. This ain't your run-of-the-mill tech stuff—it's groundbreaking in understanding physician decision-making. The Core: How Do Doctors Really...

Continue Reading
Lilly's Sofe-M Shakes Up Ovarian Cancer Treatment

Updated Category News Views 111

Ovarian Cancer Treatment Sees a New Challenger Alright, folks, Eli Lilly (NYSE:LLY) is stepping up with their latest findings in ovarian cancer treatment, and it's got plenty of people in a buzz. They've dropped new data for their investigational drug, Sofetabart mipitecan, or 'Sofe-M' for short, which targets this unrelenting disease with a punch that’s hard to ignore....

Continue Reading
AZ Health Workers Step Up for Community Wellness

Updated Category News Views 4

Health Screenings: A Step Before the Hospital Sometimes it's the basics, like a plain old health screening, that can shift the tides from crisis to care. That's exactly where AZ Blue Health Choice and Zeihan ProHealth come into the picture, aiming to pin those health concerns before they spiral out of control. For your average Arizonan who finds healthcare as elusive as a...

Continue Reading
Enigmata Innovates AI Security with Finovifi Tie-Up

Updated Category News Views 94

Emerging AI Risks and Protective Measures AI in financial spaces is like walking a tightrope, there's potential but caution is crucial. Enter Enigmata, diving headfirst into this arena by shaking hands with the Finovifi Marketplace. Their aim? To bolster AI's promise without letting sensitive data slip through the cracks. Sentinel: A New Guard for Sensitive Data Let's not...

Continue Reading
Podcast Giants Converge in Tennessee for POD U Summit

Updated Category News Views 57

Nashville Becomes a Hotspot for Podcasters Amidst the strumming guitars and honky-tonk vibes of Nashville, Tennessee transformed into the epicenter of podcasting innovation thanks to Rebel Audio's inaugural summit, POD U. Here we had big names like Mike 'Big Mike' Majlak rubbing shoulders with sports experts and media moguls—a true concoction of voices shaping the...

Continue Reading
Home Insurance Gaps: Risky Assumptions Uncovered

Updated Category News Views 53

Unseen Threats to Homeownership Safety Liability gaps in insurance are like those stubborn stains on the carpet you keep missing—nearly invisible until you're flat on your face. In Alpharetta and Fulton County, homes aren't as secure from financial pitfalls as their charming façades suggest. So, what's the danger that folks are glossing over here? Hidden Dangers of...

Continue Reading
Americas Cardroom Smashes Prize Pools; Bahamas Up Next

Updated Category News Views 49

Ah, poker. Where dreams are won with a flick of the wrist and a well-placed bluff. This week, it was all eyes on Americas Cardroom’s Dual Venom PKOs, and let me tell you, they didn't just meet expectations—they chewed them up and spat them out like yesterday's jam. Two Titans Crowned in Poker Showdown The action wrapped up with a jaw-dropping $6,862,500 prize pool....

Continue Reading
Honeywell Aerospace Faces Class Action: Deadline Looms

Updated Category News Views 37

Navigating the Legal Storm with Honeywell Look, investors never have it easy, and when lawsuits start flying like today's news about Honeywell Aerospace, you better have your wits about you. Now here comes Kahn Swick & Foti, LLC, ringing the alarm bells. Any holders of Honeywell Aerospace stocks between late June and early September of '26 are squarely in the spotlight....

Continue Reading
Savvy Moves: Avoiding Pitfalls When Buying Used Vans

Updated Category News Views 14

When you're eyeing a used work van, don't just kick the tires and jot down the mileage—there's a whole backyard BBQ checklist you need to chew through. Tony Collichio, the work van guru from Spencerport, lays it down for us, highlighting key questions to ask before pulling out the checkbook. And let me tell you, these aren’t your everyday 'how does it drive?' queries....

Continue Reading
Abbott's Oncodetect Test: Game-Changer for Cancer Recurrence

Updated Category News Views 4

Pioneering Progress in Colorectal Cancer Detection There's a new player in the world of cancer diagnostics, and it's setting a fresh standard. Abbott's Oncodetect test, featured at the ESMO Congress, has shown a profound leap in sensitivity—30 percent over the older whole-exome sequencing approach. For those doing the math on the stock charts, Abbott (NYSE: ABT) is...

Continue Reading

Top 5 Most Recently Viewed Articles

Clare Locke Advocates for Megan Thee Stallion in Defamation Case

Updated Category News Views 111

Clare Locke LLP Champions Megan Thee Stallion's Defamation Case Clare Locke LLP, a respected name in defamation law, has taken a bold step to support Megan Thee Stallion's pursuit of justice against Milagro Cooper. The firm has filed a motion for leave to present an amicus brief that specifically endorses Megan's effort to have a jury's defamation ruling reinstated. This...

Continue Reading
Bankers Signal Looming Economic Challenges Amid Uncertainty

Updated Category News Views 167

Bankers Signal Looming Economic Challenges Amid Uncertainty Interest rate fluctuations, credit quality, and tariffs are significant concerns for financial institutions. A recent survey highlights the anxiety among bankers regarding the economic climate and impending recession. Survey Highlights Economic Fears According to a survey from fintech IntraFi, which gathered...

Continue Reading
Dave Portnoy Questions Elon Musk Amid Tesla's Plummeting Stock

Updated Category News Views 162

Tesla's Stock Dilemma: Portnoy's Concerns Tesla’s stock, designated as TSLA, has recently experienced a significant decline, stirring up discussions among investors and enthusiasts alike. Dave Portnoy, the founder of Barstool Sports, has voiced his frustration regarding this situation, bringing forth some pointed questions about Elon Musk’s priorities. In a recent...

Continue Reading
Akropolis Group's Credit Rating Affirmed Amid Strategic Changes

Updated Category News Views 88

Akropolis Group’s Robust Credit Rating Amid Strategic Reassessments Renowned international credit rating agency S&P Global Ratings recently evaluated the financial outlook for Akropolis Group, a prominent player in the real estate development and management sector. This assessment took into account significant structural governance changes within the Vilniaus Prekyba...

Continue Reading
Arcutis Takes a Significant Step with ZORYVE Cream for Kids

Updated Category News Views 156

Arcutis Advances ZORYVE® Cream for Pediatric Use Arcutis Biotherapeutics, Inc. is making headlines with its recent submission of a supplemental New Drug Application (sNDA) aimed at expanding the use of ZORYVE (roflumilast) cream 0.3% to treat plaque psoriasis in children as young as 2 years old. If approved, ZORYVE would be the first topical PDE4 inhibitor specifically...

Continue Reading